Lidocaine Hcl

證據等級: L5

預測適應症: 0 個

LIDOCAINE HCL: Local Anesthetic / Antiarrhythmic — No TxGNN Repurposing Predictions Generated

One-Sentence Summary

Lidocaine HCl is a widely used local anesthetic and antiarrhythmic agent with 21 registered products in Malaysia. The current TxGNN analysis run did not generate any repurposing predictions for this compound, and critical data gaps in mechanism of action, approved indications, and safety information prevent a complete evaluation at this stage.

Quick Overview

Item	Content
Original Indication	Not retrieved in current dataset
Predicted New Indication	No predictions generated
TxGNN Prediction Score	N/A
Evidence Level	L5 – No model prediction output
Malaysia Market Status	✓ Marketed
Number of Registrations	21
Recommended Decision	Hold

Why Is No Prediction Available?

TxGNN requires a valid DrugBank ID to anchor a compound in the knowledge graph and generate repurposing scores. In this Evidence Pack, drugbank_id is null, meaning the pipeline could not map Lidocaine HCl to a knowledge graph node. Without this anchor, the model produces no ranked disease candidates.

Additionally, the original_indications array is empty and original_moa is unavailable, removing the biological context needed to validate any mechanistic rationale even if predictions were present.

Currently, detailed mechanism of action data is not available. Based on general pharmacological knowledge, Lidocaine HCl is a sodium channel blocker used as a local anesthetic and Class Ib antiarrhythmic drug; however, this information was not confirmed in the supplied Evidence Pack and should not be used for formal evaluation without verified sourcing.

Clinical Trial Evidence

Currently no related clinical trials registered (no predicted indication to search against).

Literature Evidence

Currently no related literature available (no predicted indication to search against).

Malaysia Market Information

A total of 21 registered products were identified via NPRA query (query date: 2026-03-27). However, individual license details — including authorization number, product name, dosage form, and approved indication text — were not retrieved in the current dataset.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	Detailed records not available; 21 registrations confirmed by NPRA

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This evaluation cannot proceed meaningfully because the TxGNN pipeline produced no repurposing candidates — a direct consequence of the missing DrugBank ID — and all drug-level data fields (original indication, mechanism of action, safety warnings, contraindications, and individual license records) are absent from the current Evidence Pack.

To proceed, the following is needed:

Resolve DrugBank ID: Look up Lidocaine HCl on DrugBank (expected: DB00281) and update the drugbank_id field, then re-run the TxGNN prediction pipeline
Retrieve NPRA license details: Query NPRA product registry for all 21 registrations to populate product names, dosage forms, and approved indication texts
Obtain MOA and safety data: Pull the DrugBank entry for pharmacodynamics, mechanism of action, warnings, contraindications, and drug–drug interactions
Parse package inserts: Download NPRA/manufacturer-approved prescribing information PDFs to confirm local warnings and contraindications (Data Gap DG001 — severity: Blocking)
Re-run evidence collection: Once a predicted indication is confirmed, trigger ClinicalTrials.gov and PubMed collectors to gather supporting literature

⚠️ YMYL Disclaimer: This report is for research reference only and does not constitute medical advice. Any drug repurposing candidate must undergo clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.